Alexandre P A Theocharides
Overview
Explore the profile of Alexandre P A Theocharides including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
433
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dietsche L, Stirm K, Lysenko V, Schneidawind C, Tzankov A, Muller A, et al.
Front Oncol
. 2025 Jan;
14:1481713.
PMID: 39834944
Introduction: -rearrangements define a subclass of acute leukemias characterized by a distinct gene expression signature linked to the dysfunctional oncogenic fusion proteins arising from various chromosomal translocations involving the (also...
2.
Wegmann R, Bonilla X, Casanova R, Chevrier S, Coelho R, Esposito C, et al.
Nat Commun
. 2024 Oct;
15(1):9402.
PMID: 39477946
Deep single-cell multi-omic profiling offers a promising approach to understand and overcome drug resistance in relapsed or refractory (rr) acute myeloid leukemia (AML). Here, we combine single-cell ex vivo drug...
3.
Theocharides A, Hutter G, Saito Y
Front Immunol
. 2024 May;
15:1418281.
PMID: 38736871
No abstract available.
4.
Wildschut M, Mena J, Dordelmann C, van Oostrum M, Hale B, Settelmeier J, et al.
Nat Commun
. 2023 Oct;
14(1):6414.
PMID: 37828014
Myelofibrosis is a hematopoietic stem cell disorder belonging to the myeloproliferative neoplasms. Myelofibrosis patients frequently carry driver mutations in either JAK2 or Calreticulin (CALR) and have limited therapeutic options. Here,...
5.
Maru B, Messikommer A, Huang L, Seipel K, Kovecses O, Valk P, et al.
Cell Rep Med
. 2023 Sep;
4(9):101191.
PMID: 37683650
Previous chemotherapy research has focused almost exclusively on apoptosis. Here, a standard frontline drug combination of cytarabine and idarubicin induces distinct features of caspase-independent, poly(ADP-ribose) polymerase 1 (PARP-1)-mediated programmed cell...
6.
Grockowiak E, Korn C, Rak J, Lysenko V, Hallou A, Panvini F, et al.
Nat Cancer
. 2023 Aug;
4(8):1193-1209.
PMID: 37550517
Aging facilitates the expansion of hematopoietic stem cells (HSCs) carrying clonal hematopoiesis-related somatic mutations and the development of myeloid malignancies, such as myeloproliferative neoplasms (MPNs). While cooperating mutations can cause...
7.
Lysenko V, Schurch P, Tuzlak S, van Wijk N, Kovtonyuk L, Becher B, et al.
Leukemia
. 2023 Apr;
37(6):1277-1286.
PMID: 37095207
Polycythemia vera (PV) is a hematopoietic stem cell neoplasm driven by somatic mutations in JAK2, leading to increased red blood cell (RBC) production uncoupled from mechanisms that regulate physiological erythropoiesis....
8.
Schurch P, Malinovska L, Hleihil M, Losa M, Hofstetter M, Wildschut M, et al.
Cell Rep
. 2022 Nov;
41(8):111689.
PMID: 36417879
Calreticulin (CALR) is an endoplasmic reticulum (ER)-retained chaperone that assists glycoproteins in obtaining their structure. CALR mutations occur in patients with myeloproliferative neoplasms (MPNs), and the ER retention of CALR...
9.
Tan G, Wolski W, Kummer S, Hofstetter M, Theocharides A, Manz M, et al.
Blood Adv
. 2022 Jan;
6(11):3480-3493.
PMID: 35008095
Polycythemia vera (PV) is a stem cell disorder characterized by hyperproliferation of the myeloid lineages and the presence of an activating JAK2 mutation. To elucidate mechanisms controlling PV stem and...
10.
Saito Y, Willinger T, Theocharides A
Front Immunol
. 2022 Jan;
12:829644.
PMID: 35003145
No abstract available.